MONITORING HEALTH AND DISEASE STATUS USING CLONOTYPE PROFILES

• US 20170349954A1
• Filed: 06/09/2017
• Published: 12/07/2017
• Est. Priority Date: 11/07/2008
• Status: Active Grant

• Current Assignee: Adaptive Biotechnologies Corp.
• Original Assignee: Adaptive Biotechnologies Corp.
• Inventors: FAHAM, Malek, WILLIS, Thomas
• Granted Patent: US 10,519,511 B2
• Time in Patent Office: Days
• CPC Class Codes: C12Q 1/6881 for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
• CPC Class Codes: C12Q 1/6883 for diseases caused by alterations of genetic material
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2600/118 Prognosis of disease development
• CPC Class Codes: C12Q 2600/156 Polymorphic or mutational markers
• CPC Class Codes: C12Q 2600/158 Expression markers
• CPC Class Codes: C12Q 2600/16 Primer sets for multiplex assays

Abstract

There is a need for improved methods for determining the diagnosis and prognosis of patients with conditions, including autoimmune disease and cancer, especially lymphoid neoplasms, such as lymphomas and leukemias. Provided herein are methods for using DNA sequencing to identify personalized, or patient-specific biomarkers in patients with lymphoid neoplasms, autoimmune disease and other conditions. Identified biomarkers can be used to determine and/or monitor the disease state for a subject with an associated lymphoid disorder or autoimmune disease or other condition. In particular, the invention provides a sensitive method for monitoring lymphoid neoplasms that undergo clonal evolutions without the need to development alternative assays for the evolved or mutated clones serving as patient-specific biomarkers.

Claims

1-74. -74. (canceled)

75. A method of determining antigen-specific T cells in a tissue sample, comprising the steps of:

dividing the tissue sample into a first subset and a second subset;

sequencing recombined nucleic acids encoding a T-cell receptor chain or a portion thereof from the first subset to provide sequence reads from which clonotypes are determined;

exposing the second subset to an antigen;

separating T cells from the second subset that interact with the antigen to obtain an enriched T cell sample;

sequencing recombined nucleic acids encoding a T-cell receptor chain or a portion thereof from the enriched T cell sample to provide sequence reads from which clonotypes are determined; and

identifying antigen-specific T cells in the tissue sample as T cells whose clonotype frequencies increase in the enriched T cell sample relative to the frequencies of the same clonotype in the first subset.

76. The method of claim 75, wherein said antigen is a protein or a plurality of peptides derived from a protein.

77. The method of claim 75, wherein said step of sequencing includes isolating individual molecules of said recombined nucleic acids on a solid surface and sequencing the isolated individual molecules or clones thereof to provide said sequence reads.

78. The method of claim 77, wherein said method further includes a step of coalescing a plurality of said sequence reads to determine each of said clonotypes.

79. The method of claim 75, wherein said step of separating includes sorting said T cells that interact with said antigen.

80. The method of claim 79, wherein said step of sorting is implemented with an antigen reagent capable of forming a complex with a T cell specific for said antigen or wherein said step of sorting is implemented with a binding compound specific for an activation marker.

81. The method of claim 80, wherein said antigen reagent is a peptide-MHC multimer complex wherein the peptide of the complex is derived from said antigen.

82. The method of claim 75, wherein said tissue sample comprises tissue samples from a plurality of individuals.

83. The method of claim 75, wherein said tissue sample comprises peripheral blood or is derived from peripheral blood.

84. A method of determining antigen-specific T cells in a tissue sample, comprising the steps of:

exposing the tissue sample to an antigen;

separating T cells that interact with the antigen from T cells that do not interact with the antigen to obtain an enriched T cell sample and an unenriched T cell sample, respectively;

sequencing recombined nucleic acids encoding a T-cell receptor chain or a portion thereof from the enriched T cell sample to provide sequence reads from which clonotypes are determined;

sequencing recombined nucleic acids encoding a T-cell receptor chain or a portion thereof from the unenriched T cell sample to provide sequence reads from which clonotypes are determined; and

identifying antigen-specific T cells in the tissue sample as T cells whose clonotype frequencies increase in the enriched T cell sample relative to the frequencies of the same clonotype in the unenriched T cell sample.

85. The method of claim 84, wherein said antigen is a protein or a plurality of peptides derived from a protein.

86. The method of claim 84, wherein said step of sequencing includes isolating individual molecules of said recombined nucleic acids on a solid surface and sequencing the isolated individual molecules or clones thereof to provide said sequence reads.

87. The method of claim 86, wherein said method further includes a step of coalescing a plurality of said sequence reads to determine each of said clonotypes.

88. The method of claim 84, wherein said step of separating includes sorting said T cells that interact with said antigen.

89. The method of claim 88, wherein said step of sorting is implemented with an antigen reagent capable of forming a complex with a T cell specific for said antigen or wherein said step of sorting is implemented with a binding compound specific for an activation marker.

90. The method of claim 89, wherein said antigen reagent is a peptide-MHC multimer complex wherein the peptide of the complex is derived from said antigen.

91. The method of claim 84, wherein said tissue sample comprises tissue samples from a plurality of individuals.

92. The method of claim 84, wherein said tissue sample comprises peripheral blood or is derived from peripheral blood.